Amneal Delivers On Biosimilars Ambitions With Neupogen Rival
Company Also Reveals Plans For 20-30 Generics Launches In 2022
Amneal has laid out its plans to enter the US biosimilars market after receiving FDA approval for its first biosimilar, a Neupogen rival known as Releuko (filgrastim-ayow) that was developed with partner Kashiv Biosciences. Amneal also intends to launch two more biosimilars soon, along with 20-30 generics launches planned in 2022.
